Radiopharm Theranostics (ASX:RAD) Accumulated other comprehensive income (loss): A$13.12 Mil (As of Jun. 2025)


What is Radiopharm Theranostics Accumulated other comprehensive income (loss)?

Radiopharm Theranostics ASX:RAD -5.00% Accumulated other comprehensive income (loss) is A$13.12 Mil as of Jun. 2025. The stock has 5 warning signs investors should review.

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Radiopharm Theranostics's Accumulated other comprehensive income (loss) for the quarter that ended in Jun. 2025 was A$13.12 Mil.

Radiopharm Theranostics's quarterly Accumulated other comprehensive income (loss) declined from Jun. 2024 (A$37.93 Mil) to Dec. 2024 (A$11.86 Mil) but then increased from Dec. 2024 (A$11.86 Mil) to Jun. 2025 (A$13.12 Mil).

Radiopharm Theranostics's annual Accumulated other comprehensive income (loss) increased from Jun. 2023 (A$10.36 Mil) to Jun. 2024 (A$37.93 Mil) but then declined from Jun. 2024 (A$37.93 Mil) to Jun. 2025 (A$13.12 Mil).

Radiopharm Theranostics Accumulated other comprehensive income (loss) Related Terms

Radiopharm Theranostics Accumulated other comprehensive income (loss) Historical Data

* Premium members only.

The historical data trend for Radiopharm Theranostics's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics Accumulated other comprehensive income (loss) Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Accumulated other comprehensive income (loss)
7.03 10.36 37.93 13.12

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial 10.36 14.20 37.93 11.86 13.12

Radiopharm Theranostics Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

What does a Accumulated other comprehensive income (loss) of A$13.12 Mil mean?
Radiopharm Theranostics (ASX:RAD) has a Accumulated other comprehensive income (loss) of A$13.12 Mil as of Jun. 2025. Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. View historical data on Radiopharm Theranostics and its competitors.
Is Radiopharm Theranostics' Accumulated other comprehensive income (loss) too high?
Radiopharm Theranostics' current Accumulated other comprehensive income (loss) is A$13.12 Mil.
How does Radiopharm Theranostics' Accumulated other comprehensive income (loss) compare to VRTX and REGN?
Radiopharm Theranostics' Accumulated other comprehensive income (loss) of A$13.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated other comprehensive income (loss) for a Biotechnology company?
A good Accumulated other comprehensive income (loss) depends on the Biotechnology industry context. However, Accumulated other comprehensive income (loss) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated other comprehensive income (loss) mean?
A high Accumulated other comprehensive income (loss) can signal that a stock is expensive relative to its fundamentals. Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. View historical data on Radiopharm Theranostics and its competitors. Radiopharm Theranostics's current Accumulated other comprehensive income (loss) is A$13.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (ASX:RAD) has a current Accumulated other comprehensive income (loss) of A$13.12 Mil. The current Accumulated other comprehensive income (loss) is A$13.12 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated other comprehensive income (loss) calculated?
Accumulated other comprehensive income (loss) is calculated from a company's financial statements. For Radiopharm Theranostics (ASX:RAD), the current Accumulated other comprehensive income (loss) is A$13.12 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radiopharm Theranostics Business Description

Other Exchanges RADX:USA
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.